De Francesco 2004a.

Methods	Randomised controlled trial Dates the study was conducted: not reported Funding sources and potential conflicts of interest: No information reported Definition of compliance: > 90% intake was considered as 'acceptable'
Participants	Number and type of participants: 97 H.pylori‐positive participants were included in the study Number of participants randomised: 97 (ITT sample) Number of participants in the 10‐day SEQ arm: 45 (group A) Number of participants in the 10‐day STT arm: 52 (group B) Country: Italy Average age (SD) of the ITT population in years, by treatment group: 10‐day SEQ (reported as group A): 44.2 (16.2) 10‐day STT (reported as group B): 46.0 (15.3) Sex (M/F) per treatment group 10‐day SEQ: 20/25 10‐day STT: 21/31 Number of participants (rate) of the ITT population per treatment group with a medical condition: ‐ NUD 10‐day SEQ: 36/45 10‐day STT: 35/52 ‐ PUD 10‐day SEQ: 9/45 10‐day STT: 11/52 At baseline, the groups were reported homogeneous with regard to sex, age, smoking habit and endoscopic findings (PUD/NUD)
Interventions	Name, dose timing of antibiotics in 10‐day STT (group B): rabeprazole 20 mg twice a day + clarithromycin 500 mg twice a day + amoxicillin 1 g twice a day (during 10 days) Name, dose timing of antibiotics in 10‐day SEQ (group A): rabeprazole 20 mg twice a day + amoxicillin 1 g twice a day (5 days) + rabeprazole 20 mg twice a day, clarithromycin 500 mg twice a day,tinidazole 500 mg twice a day (5 days) Sensitivity test (yes/no) to antibiotics before/after treatment: no Method of assessment of H. pylori status after treatment: ¹³C‐UBT Time for assessment of H. pylori status after treatment: 6 ‐ 8 weeks
Outcomes	95 participants completed the study: 2/45 (2%) did not return after therapy for unreported reasons (1 PUD in group A and 1 NUD in group B) ITT eradication rate (%) by treatment group and PP: 10‐day SEQ: 43/45 (95.5) 10‐day STT: 42/52 (80.7) PP eradication rate (%) by treatment group: 10‐day SEQ: 43/44 (97.7) 10‐day STT: 42/51 (82.3) ITT eradication rate (%) in NUD participants: 60/70 (85.7) ITT eradication rate (%) in PUD participants: 25/25 (100) Metronidazole resistance (%) before treatment, SEQ ITT/PP:not reported Metronidazole resistance (%) before treatment, STT ITT/PP:not reported Clarithromycin resistance (%) before treatment, SEQ ITT/PP:not reported Clarithromycin resistance (%) before treatment, STT ITT/PP:not reported Compliance (%) in ITT sample SEQ/STT: not reported Incidence (%) of AEs SEQ/7‐day STT ‐ 10‐day STT: not reported Incidence (%) serious AEs SEQ/STT: not reported
Notes
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Truly randomised study by a computer‐generated list
Allocation concealment (selection bias)	Unclear risk	No information was reported
Incomplete outcome data (attrition bias) All outcomes	Low risk	Primary outcome data were clearly reported
Blinding of participants and personnel (performance bias) All outcomes	Unclear risk	No information was reported
Publication format	Low risk	Full article